Kiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Earnings Results

Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11), Briefing.com reports. The firm had revenue of $79.90 million for the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. Kiniksa Pharmaceuticals’s revenue was up 65.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.18) EPS.

Kiniksa Pharmaceuticals Stock Up 4.2 %

NASDAQ:KNSA traded up $0.75 during trading hours on Wednesday, reaching $18.43. 56,562 shares of the stock were exchanged, compared to its average volume of 398,310. The business has a 50-day moving average of $19.36 and a two-hundred day moving average of $18.00. Kiniksa Pharmaceuticals has a twelve month low of $10.65 and a twelve month high of $22.09. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 100.84 and a beta of 0.27.

Insiders Place Their Bets

In other news, CEO Sanj K. Patel sold 5,582 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total value of $117,222.00. Following the sale, the chief executive officer now directly owns 65,012 shares in the company, valued at $1,365,252. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the transaction, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at $383,242.52. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Sanj K. Patel sold 5,582 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total value of $117,222.00. Following the transaction, the chief executive officer now directly owns 65,012 shares in the company, valued at approximately $1,365,252. The disclosure for this sale can be found here. Insiders have sold 33,109 shares of company stock worth $709,929 over the last ninety days. Corporate insiders own 54.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on KNSA shares. TheStreet upgraded Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Tuesday.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.